BridgeBio Pharma Stock Down, Month 12 Topline Results from Phase 3 ATTRibute-CM Study Released
BridgeBio Pharma, Inc. (NASDAQ: BBIO) stock crushed about 70% after the biotech company announced results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)....